Skip To Main Content
Irving Barrera on Muck Rack

Irving Barrera

As seen in: Cell Press
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Irving

Contact Irving, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

CRATER tumor niches facilitate CD8+ T cell engagement and correspond with immunotherapy success

|
By Aya Ludin, Georgia L. Stirtz, Asaf Tal, Ajit J Nirmal, Kathleen L. Pfaff, Michael Manos, Naomi R. Besson, Nebiyat Eskndir, Billie JD Porter, Stephanie Jones, Hannah Faulkner, Qiyu Gong, Sophia B. Liu, Irving Barrera, Lijian Wu, Cecilia Pessoa Rodrigues, Cecília Rodrigues, Aditi Sahu, Elizabeth R. Jerison, Joao V Alessi, Biagio Ricciuti, Douglas Richardson, Jodi Weiss, Hadley Moreau, Alexander B. Afeyan, James Sefton, Yi Zhou, Hannah Cole, Miguel Cordova, Liang Deng, Milind Rajadhyaksha, Stephen R. Quake, Mark Awad, fei chen, Kai W. Wucherpfennig, Peter K. Sorger, F. Stephen Hodi, Scott J. Rodig, George Murphy, Leonard I. Zon, Meredith E. Stanhope, Wyatt D. McCall, Emily Formato
| Cell Press Verified
Keywords melanoma immune response immunotherapy zebrafish CD8+ T cells cancer Introduction Immune checkpoint blockade (ICB) cancer therapy, re-activating CD8+ T cells against tumors, has significantly increased patients’ life expectancy and survival.1,2 ICB initiates CD8+ T cell infiltration and results in necrosis, fibrosis, and shrinkage.
Open in Who Shared Issue with article?
See all 1 articles